There has been an increasing demand for the development of nanocarriers targeting
multiple diseases with a broad range of properties. Due to their tiny size, giant surface area …

The treatment of the posterior-segment ocular diseases, such as age-related eye diseases
(AMD) or diabetic retinopathy (DR), present a challenge for ophthalmologists due to the …

Drug delivery to the posterior eye segment is an important challenge in ophthalmology,
because many diseases affect the retina and choroid leading to impaired vision or …

Aims/hypothesis The pathophysiology of diabetic retinopathy is linked to hyperglycaemia
and its effect on retinal microvascular tissues. The resulting endothelial injury changes the …

Diabetic retinopathy (DR), a sight-threatening neurovasculopathy, is the leading cause of
irreversible blindness in the developed world. DR arises as the result of prolonged …

Intravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodies has
become the standard treatment for Age-Related Macular Degeneration; however, the …

Diabetic retinopathy (DR) is one of the leading causes of visual impairment in the working-
age population. DR is a progressive eye disease caused by long-term accumulation of …

Diabetic retinopathy (DR) is a sight-threatening complication of both type-1 and type-2
diabetes. The recent success of treatments inhibiting the function of vascular endothelial …

Nanocarriers (synthetic/cell-based have attracted enormous interest for various therapeutic
indications, including neurodegenerative disorders. A broader understanding of the impact …

Eye injury is a significant disabling worldwide health problem. Proliferative Vitreoretinopathy
(PVR) is a common complication that develops in up to 40–60% of patients with an open …